4.7 Article

Metabolomic and lipidomic signatures in autosomal dominant and late-onset Alzheimer's disease brains

期刊

ALZHEIMERS & DEMENTIA
卷 -, 期 -, 页码 -

出版社

WILEY
DOI: 10.1002/alz.12800

关键词

APOE; APP; autosomal dominant Alzheimer's disease; beta-citrylglutamate; lipidomics; metabolomics; PSEN1; PSEN2; TREM2

资金

  1. Dominantly Inherited Alzheimer Network (DIAN) - National Institute on Aging (NIA) [U19AG032438]
  2. Alzheimer's Association [SG-20-690363-DIAN]
  3. German Center for Neurodegenerative Diseases (DZNE)
  4. Raul Carrea Institute for Neurological Research (FLENI)
  5. Research and Development Grants for Dementia from Japan Agency for Medical Research and Development
  6. AMED
  7. Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI)
  8. Spanish Institute of Health Carlos III (ISCIII)
  9. Canadian Institutes of Health Research (CIHR)
  10. Canadian Consortium of Neurodegeneration and Aging
  11. Brain Canada Foundation
  12. Fonds de Recherche du Quebec - Sante
  13. NIA [R01AG046171, RF1AG051550, 3U01AG024904-09S4, RF1AG057452, R01AG059093, RF1AG058942, U01AG061359, U19AG063744]
  14. FNIH [DAOU16AMPA]
  15. Alzheimer's Disease Neuroimaging Initiative (ADNI) [U01 AG024904]
  16. DOD ADNI [W81XWH-12-2-0012]
  17. National Institute on Aging
  18. National Institute of Biomedical Imaging and Bioengineering
  19. AbbVie
  20. Alzheimer's Association
  21. Alzheimer's Drug Discovery Foundation
  22. Araclon Biotech
  23. BioClinica, Inc.
  24. Biogen
  25. Bristol-Myers Squibb Company
  26. CereSpir, Inc.
  27. Cogstate
  28. Eisai Inc.
  29. Elan Pharmaceuticals, Inc.
  30. Eli Lilly and Company
  31. EuroImmun
  32. F. Hoffmann-La Roche Ltd
  33. affiliated company Genentech, Inc.
  34. Fujirebio
  35. GE Healthcare
  36. IXICO Ltd.
  37. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  38. Johnson & Johnson Pharmaceutical Research & Development LLC
  39. Lumosity
  40. Lundbeck
  41. Merck Co., Inc.
  42. Meso Scale Diagnostics, LLC.
  43. NeuroRx Research
  44. Neurotrack Technologies
  45. Novartis Pharmaceuticals Corporation
  46. Pfizer Inc.
  47. Piramal Imaging
  48. Servier
  49. Takeda Pharmaceutical Company
  50. Transition Therapeutics
  51. Canadian Institutes of Health Research
  52. The NIA [P30AG10161, R01AG1581, R01AG17917, R01AG30146, R01AG36042, RC2AG036547, R01AG36836, R01AG48015, RF1AG57473, U01AG32984, U01AG46152, U01AG46161, U01AG61356, 3R01AG046171-02S2, R01AG15819, U01AG32984 U01AG46152]
  53. Illinois Department of Public Health
  54. Translational Genomics Research Institute
  55. National Institute of Health [NIA R01AG057777, RO1AG057777-02S1, K99AG061281, P30AG066444, P01AGO26276, NINDS R01NS118146, R01AG044546, P01AG003991, RF1AG053303, RF1AG058501, U01AG058922]
  56. Chan Zuckerberg Initiative (CZI)

向作者/读者索取更多资源

Metabolomic analysis reveals distinct metabolic features in carriers of different genetic risk factors for Alzheimer's disease, providing insights into the etiology and clinical presentation of the disease.
Introduction: The identification of multiple genetic risk factors for Alzheimer's disease (AD) suggests that many pathways contribute to AD onset and progression. However, the metabolomic and lipidomic profiles in carriers of distinct genetic risk factors are not fully understood. The metabolome can provide a direct image of dysregulated pathways in the brain. Methods: We interrogated metabolomic signatures in the AD brain, including carriers of pathogenic variants in APP, PSEN1, and PSEN2 (autosomal dominant AD; ADAD), APOE epsilon 4, and TREM2 risk variant carriers, and sporadic AD (sAD). Results: We identified 133 unique and shared metabolites associated with ADAD, TREM2, and sAD. We identified a signature of 16 metabolites significantly altered between groups and associated with AD duration. Discussion: AD genetic variants show distinct metabolic perturbations. Investigation of these metabolites may provide greater insight into the etiology of AD and its impact on clinical presentation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据